Ex-Pharma Exec Seeks Leniency After SEC Contempt Plea

By Brian Dowling · July 29, 2024, 1:36 PM EDT

A former pharmaceutical executive is hoping to avoid jail after his use of an alias to circumvent a U.S. Securities and Exchange Commission ban on finance work landed him a criminal...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Case Number

Court

Massachusetts

Nature of Suit

Date Filed

February 21, 2024

Recent Articles By Brian

July 12, 2024
Boston To Pay $1M To End Health Dept. Harassment Case
July 10, 2024
Drug Test Co. Pays $1M To Settle Medicare Fraud Claims
June 10, 2024
Medical-Aesthetic Device Rivals Set For Sept. Poaching Trial
May 29, 2024
Whistleblower Counsel Can't Get 'Exorbitant' $11.5M Fee
May 17, 2024
FCA Relators Seek Finders Fee For SpineFrontier Doc Deals
May 17, 2024
Mass. Hospital Pays $24.3M To Settle Heart-Surgery FCA Case
May 16, 2024
Ex-Pharma Exec Cops To Contempt For Barred Finance Work
April 22, 2024
Dentist Must Face Harassment Suit, Mass. Panel Says
March 28, 2024
Implant Maker's Bribe Case Ripe For Trimming, Judge Says
March 26, 2024
Ex-Veterans Home Leaders Resolve Landmark COVID-19 Case